A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Procopio Giuseppe
Main Facility: Oncologia Medica Genitourinaria
Drug: Opevesostat (MK-5684) + hormone replacement therapy (HRT) // abiraterone acetate or enzalutamide
Pathologies: Prostate tumors
Eligible participants will be randomly assigned in a 1:1 ratio to receive treatment with either MK-5684 plus HRT or alternative abiraterone acetate or enzalutamide. Randomization will be stratified according to the participants measurable disease (yes vs no), AR LBD mutation status (yes vs no) and prior cabazitaxel treatment (yes vs no).
Last update: 21/04/2026